2025-05-22 Drugs The SFDA Grants Breakthrough Designation to “MIQNAF” for Acute Bacterial Infections Treatment
2025-05-13 Drugs The SFDA Grants Breakthrough Designation to Atrasentan (Vanrafia) for Primary Immunoglobulin A (IgA) Nephropathy
2025-05-05 Drugs The SFDA Approves Breakthrough Designation Application for Breast Cancer Therapy “Inluriyo”
2025-05-04 Drugs The SFDA Approves Clinical Trial for Novel Biologic Therapy for Genetic Propionic Acidemia
2009-12-14 The Authority Early Communication about an Ongoing Safety Review of Reductil (sibutramine hydrochloride)
